MTOR and non-small cell lung carcinoma: For instance, the combination of rapamycin and anti-PD-1 antibody has dampened the progression of NSCLC 47, with the pharmacological effect of rapamycin on inhibiting the activation of the AKT/mTOR pathway from differentiating CD3+ T cells 101.